Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of quavonlimab (MK-1308) plus pembrolizumab in advanced solid tumors
jRCT2080223764Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of pembrolizumab and quavonlimab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (7 arms), sponsored by Merck & Co. Started Dec 2017; status: completed.
02
Drugs
pembrolizumabquavonlimab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2080223764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223764.